# PaxMedica (NASDAQ: PXMD) Shares Corporate Update, Commitment to Advancing Therapies for Neurological Disorders

* PaxMedica is preparing to submit a New Drug Application to the U.S. Food and Drug Administration later this year for using suramin to treat Human African Trypanosomiasis
* PaxMedica is currently preparing for an associated and very important Type C meeting with the FDA scheduled for June 27th
* Type C meetings are designated by the FDA to address specific issues in drug development, such as clinical trial design, data requirements, or other scientific matters not covered by Type A or Type B meetings

 PaxMedica (NASDAQ: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, recently shared corporate updates regarding its continued progress toward establishing suramin as an accepted treatment for Human African Trypanosomiasis (“HAT”).

 PaxMedica is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for using suramin to treat Human African Trypanosomiasis, a well-established treatment in East Africa for nearly a century. In April 2024, PaxMedica demonstrated its commitment to…

 Read More>>

 NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

 Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

 The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

 Corporate Communications

 IBN (InvestorBrandNetwork)Los Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ult-prem/paxmedica-nasdaq-pxmd-shares-corporate-update-commitment-to-advancing-therapies-for-neurological-disorders/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/paxmedica-prepares-nda-submission-for-suramin-to-treat-human-african-trypanosomiasis/a8490a3f58111f7a5009b729002fc952) 

 



[Reddit Post](https://www.reddit.com/r/Leadership_Management/comments/1f2pw8k/paxmedica_prepares_nda_submission_for_suramin_to/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/248/27/bendiANH.webp)